BR9917005A - Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete - Google Patents

Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete

Info

Publication number
BR9917005A
BR9917005A BR9917005-1A BR9917005A BR9917005A BR 9917005 A BR9917005 A BR 9917005A BR 9917005 A BR9917005 A BR 9917005A BR 9917005 A BR9917005 A BR 9917005A
Authority
BR
Brazil
Prior art keywords
insulin
diabetes
treatment
combination
insulin sensitizers
Prior art date
Application number
BR9917005-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Mark D Erion
Paul Van Poelje
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of BR9917005A publication Critical patent/BR9917005A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR9917005-1A 1998-12-24 1999-12-22 Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete BR9917005A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
PCT/US1999/030713 WO2000038666A2 (en) 1998-12-24 1999-12-22 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES

Publications (1)

Publication Number Publication Date
BR9917005A true BR9917005A (pt) 2002-04-02

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9917005-1A BR9917005A (pt) 1998-12-24 1999-12-22 Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete

Country Status (25)

Country Link
EP (1) EP1143955B1 (https=)
JP (1) JP2003515523A (https=)
KR (3) KR20060114724A (https=)
CN (3) CN101164618A (https=)
AT (1) ATE300288T1 (https=)
AU (1) AU771039B2 (https=)
BR (1) BR9917005A (https=)
CA (1) CA2354053A1 (https=)
CZ (1) CZ20012353A3 (https=)
DE (1) DE69926400T2 (https=)
DK (1) DK1143955T3 (https=)
ES (1) ES2246586T3 (https=)
HK (1) HK1046863B (https=)
HU (1) HUP0402506A3 (https=)
ID (1) ID30237A (https=)
IL (2) IL143569A0 (https=)
MX (1) MXPA01006511A (https=)
NO (1) NO20013115L (https=)
NZ (1) NZ512219A (https=)
PL (1) PL352756A1 (https=)
PT (1) PT1143955E (https=)
RU (2) RU2227749C2 (https=)
SK (1) SK9172001A3 (https=)
WO (1) WO2000038666A2 (https=)
ZA (1) ZA200105016B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
ATE246197T1 (de) 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
CA2396713A1 (en) 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US6919322B2 (en) 2000-03-08 2005-07-19 Metabasis Therapeutics, Inc. Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
IL153513A0 (en) * 2000-07-06 2003-07-06 Metabasis Therapeutics Inc A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
CA2429426A1 (en) 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EA009919B1 (ru) * 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
CA2551611C (en) * 2003-12-26 2013-06-25 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−1,6−ビスホスファターゼの新規チアゾール阻害物質
WO2006064744A1 (ja) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited 糖尿病の治療のための医薬組成物
BRPI0519015A2 (pt) * 2004-12-15 2008-12-23 Daiichi Sankyo Co Ltd composiÇço farmacÊutica, agente profilÁtico ou agente terapÊutico, agentes para melhorar a funÇço das cÉlulas b no pÂncreas, e para a reduÇço da razço da hemoglobina glicosilada, e, usos da 5-[4-(6-metàxi-1-metil-1h-benzimidazol-2-ilmetàxi)benzi l] tiazolidina-2,4-diona ou de um sal farmacologicamente aceitÁvel da mesma e de um inibidor de fbpase, e do 2-amino-5-isobutil-4-[2-[5-(n,n'-bis((s)-1etoxicarbonil)eti l) fosfonamido] furanil} tiazol ou de um sal farmacologicamente aceitÁvel do mesmo
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
WO2006137527A1 (ja) 2005-06-23 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. チアゾール誘導体
WO2008063842A2 (en) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びage生成阻害剤
EP0427799B1 (en) * 1989-01-24 1994-11-30 Gensia, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
HUP0402506A2 (hu) 2005-04-28
RU2003132054A (ru) 2005-04-20
DE69926400T2 (de) 2006-05-24
AU2058300A (en) 2000-07-31
WO2000038666A3 (en) 2001-11-29
KR20060114724A (ko) 2006-11-07
HUP0402506A3 (en) 2007-05-29
KR100689943B1 (ko) 2007-03-08
PL352756A1 (en) 2003-09-08
ATE300288T1 (de) 2005-08-15
SK9172001A3 (en) 2002-04-04
EP1143955A2 (en) 2001-10-17
CN101164618A (zh) 2008-04-23
NZ512219A (en) 2004-12-24
NO20013115L (no) 2001-08-24
CA2354053A1 (en) 2000-07-06
DK1143955T3 (da) 2005-11-14
ID30237A (id) 2001-11-15
RU2227749C2 (ru) 2004-04-27
HK1046863A1 (zh) 2003-01-30
PT1143955E (pt) 2005-11-30
WO2000038666A2 (en) 2000-07-06
KR20010099942A (ko) 2001-11-09
AU771039B2 (en) 2004-03-11
KR20070046210A (ko) 2007-05-02
JP2003515523A (ja) 2003-05-07
ZA200105016B (en) 2002-09-19
HK1046863B (zh) 2008-07-25
NO20013115D0 (no) 2001-06-21
MXPA01006511A (es) 2004-03-19
ES2246586T3 (es) 2006-02-16
EP1143955A3 (en) 2002-08-28
DE69926400D1 (de) 2005-09-01
CN1350466A (zh) 2002-05-22
EP1143955B1 (en) 2005-07-27
IL143569A0 (en) 2002-04-21
CN1714866A (zh) 2006-01-04
IL143569A (en) 2006-06-11
CN100352505C (zh) 2007-12-05
CZ20012353A3 (cs) 2001-12-12

Similar Documents

Publication Publication Date Title
BR9917005A (pt) Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
EA200401365A1 (ru) Способы лечения илеуса
BR0009167A (pt) Inibidores de enzima impdh
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
NO20052348L (no) Behandling av hemoragisk sjokk
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
ITMI931649A1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
Wittig et al. Endothelial-dependent S-Sulfhydration of tissue factor pathway inhibitor regulates blood coagulation
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0308415A (pt) Métodos de tratamento de diabetes usando-se inibidores de pde11a
BR9809301A (pt) "sequências de dna codificando para a subunidade chld de quelatases de magnésio vegetais bem como processos para a determinação da atividade de quelatases de magnésio vegetais"
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
ATE398134T1 (de) Neue analoga von nitrobenzylthioinosin
NO20001812L (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/185, A61K 31/192, A61K 31/203, A61K 31/421, A61K 31/426, A61K 31/427, A61K 31/4439, A61K 31/665, A61K 31/662, A61K 31/664, A61K 31/665, A61K 31/675, A61K 31/7056, A61K 31/7042, A61K 33/00, A61K 45/06, A61P 3/00, A61P 3/04, A61P 3/08, A61P 3/10, A61P 9/12, A61P 15/00

Ipc: A61K 31/00 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O, 10 (VIII), 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.